Pharmaceutical

MABS-139 by Manhattan Biosolutions for Solid Tumor: Likelihood of Approval

MABS-139 is under clinical development by Manhattan Biosolutions and currently in Phase I for Solid Tumor.

Dec 20, 2023 - 18:00
MABS-139 is under clinical development by Manhattan Biosolutions and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

ND-10 ER by Theialife Sciences for Myopia: Likelihood of Approval

Next Article

FDA receives first-ever MDMA drug application

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Otsuka Pharmaceutical agrees to buy Mindset Pharma

Otsuka Pharmaceutical agrees to buy Mindset Pharma

Sep 1, 2023

STAT+: Pharmalittle: Genentech weighs delaying cancer therapy after drug pricing law; Novo continues to restrict supplies of low-dose Wegovy

STAT+: Pharmalittle: Genentech weighs delaying cancer t...

Aug 11, 2023

CHMP recommends full marketing approval for Gilead Sciences’ Hepcludex

CHMP recommends full marketing approval for Gilead Scie...

May 6, 2023